Stimulation of Suicidal Erythrocyte Death by Methylglyoxal

Jan P. Nicolay¹, Juliane Schneider¹, Olivier M. Niemoeller¹, Ferruh Artunc¹, Manuel Portero-Otin², George Haik Jr.³, Paul J. Thornalley², Erwin Schleicher⁴, Thomas Wieder¹ and Florian Lang¹

¹Department of Physiology, and ⁴Department of Internal Medicine, University of Tübingen, ²Department of Biological Sciences, University of Essex, ³George Haik Eye Clinic, New Orleans, Louisiana

Key Words

Cell volume • Phosphatidylserine • Cation channels
• Calcium • Apoptosis • Glycolysis

Abstract

Diabetes increases the percentage of circulating erythrocytes exposing phosphatidylserine (PS) at the cell surface. PS-exposing erythrocytes are recognized, bound, engulfed and degraded by macrophages. Thus, PS exposure, a feature of suicidal erythrocyte death or eryptosis, accelerates clearance of affected erythrocytes from circulating blood. Moreover, PS-exposing erythrocytes bind to the vascular wall thus interfering with microcirculation. The present study explored mechanisms involved in the triggering of PS exposure by methylglyoxal, an extra- and intracellular metabolite which is enhanced in diabetes. PS exposure, cell size and cytosolic Ca^{2+} -activity after methylglyoxal treatment were measured by FACS analysis of annexin V binding, forward scatter and Fluo-3-fluorescence, respectively, and it was shown that the treatment significantly enhanced the percentage of PS-exposing erythrocytes at concentrations (0.3 μM) encountered in diabetic patients. Surprisingly, methylglyoxal did not

significantly increase cytosolic Ca^{2+} concentration, and at concentrations up to 3 μM , did not decrease the forward scatter. Instead, exposure to methylglyoxal inhibited glycolysis thus decreasing ATP and GSH concentrations. In conclusion, methylglyoxal impairs energy production and anti-oxidative defense, effects contributing to the enhanced PS exposure of circulating erythrocytes and eventually resulting in anemia and deranged microcirculation.

Copyright © 2006 S. Karger AG, Basel

Introduction

Diabetes is known to decrease the life span of erythrocytes [1]. The shortened survival is presumably due to triggering of phosphatidylserine exposure [2-5]. As macrophages are equipped with receptors specific for phosphatidylserine [6-8], erythrocytes exposing phosphatidylserine at their surface will be rapidly recognized, engulfed and degraded [9, 10].

Recent experiments allowed some insight into the mechanisms involved in the stimulation of phosphatidylserine exposure. Treatment of erythrocytes with the Ca^{2+} ionophore ionomycin leads to Ca^{2+} -mediated eryth-

rocyte shrinkage, membrane blebbing and breakdown of cell membrane phosphatidylserine asymmetry, all features typical for programmed cell death or apoptosis of nucleated cells [11-14]. In contrast to nucleated cells, however, Ca^{2+} -triggered programmed cell death of erythrocytes occurs in the absence of caspase activation, DNA fragmentation and mitochondrial depolarisation [11-14]. To describe this particular programmed death of erythrocytes, the term eryptosis was coined recently [15]. Eryptosis is induced by different well-known proapoptotic stressors, namely hyperosmotic shock, oxidative stress and energy depletion, which all activate Ca^{2+} -permeable unselective cation channels allowing Ca^{2+} entry [14, 16, 17]. The resulting increase of cytosolic Ca^{2+} activity triggers erythrocyte cell membrane scrambling with subsequent breakdown of the phosphatidylserine asymmetry [18, 19]. Erythrocyte Ca^{2+} entry [20] and phosphatidylserine exposure [21] have further been observed following activation of protein kinase C. Eryptosis shares some mechanisms of but may be distinct from other types of suicidal erythrocyte death, such as erythrocyte senescence [15, 22-24] or neocytolysis [25].

Metabolites known to be increased during hyperglycemia of diabetes include methylglyoxal [26-30], which has further been shown to be enhanced in chronic renal failure [31, 32]. The link between hyperglycemia and enhanced methylglyoxal formation has been clearly demonstrated by incubation of erythrocytes to elevated glucose concentrations resulting in an increased triosephosphate pool of glycolytic intermediates and a subsequent increase in the methylglyoxal concentration [33-35]. Furthermore, methylglyoxal has been implicated in the pathophysiology of vascular and renal disease [36-42] and shown to induce neuronal injury [43].

The present study has been performed to elucidate the putative role of methylglyoxal in the stimulation of phosphatidylserine exposure of erythrocytes.

Materials and Methods

Assay of methylglyoxal in human blood plasma and red blood cells

Type 1 diabetic patients and age-matched normal healthy human subjects were recruited from patients and staff of the George Haik Eye Clinic (New Orleans, LA, USA) with their informed consent. The research was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association and was approved by the local Ethics Committee. Twenty-one normal subjects (10 male, 21 female) of age 60 ± 17 years had a mean plasma glucose concentration of 5.9 ± 0.7 mM and a mean HbA_{1c} of 5.8 ± 0.5 %. Thirty-one type 1 diabetic

patients were recruited (13 male, 18 female) of age 64 ± 14 years, duration of diabetes 20 ± 9 years, plasma glucose concentration 9.3 ± 5.0 mM and HbA_{1c} 8.3 ± 1.6 %. Blood was collected from subjects with informed consent by intravenous puncture with heparin as anticoagulant. The plasma was separated by centrifugation immediately (2,000 g, 5 min), plasma and red blood cells mixed with one volume of 100 mM and 500 mM acetic acid, respectively (to prevent analyte formation during storage and processing) and shipped and stored in liquid nitrogen until processed further for analysis. Methylglyoxal was determined by derivatisation with 1,2-diamino-4,5-dimethoxybenzene and quantitation of the quinoxaline derivative by reversed phase HPLC with fluorimetric detection as described earlier [44].

Cells and solutions

Human erythrocytes were drawn from healthy volunteers and used either without purification or after separation by centrifugation for 25 min; 2000 g over Ficoll (Biochrom KG, Berlin, Germany). Experiments were performed at 37°C in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO_4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)/NaOH, 5 glucose, 1 CaCl_2 ; pH 7.4.

Where indicated, methylglyoxal (Sigma, Taufkirchen, Germany) has been added at the final concentrations as indicated. Since methylglyoxal is rapidly degraded [45], the indicated amount of methylglyoxal has been added consecutively every 60 min for up to 8 hours. In some experiments, the Ca^{2+} ionophore ionomycin (Sigma) was diluted into Ringer solution from a 1 mM dimethylsulfoxide (DMSO) stock solution. Appropriate amounts of solvent were added to control erythrocyte suspensions.

FACS analysis

FACS analysis was performed as described previously [14]. After incubation of erythrocytes (0.3 % or 6 % hematocrit) for 24 or 48 h with the respective solutions, cells were washed in annexin V-binding buffer containing 125 mM NaCl, 10 mM HEPES (pH 7.4), and 5 mM CaCl_2 . Erythrocytes were stained with Annexin-Fluos (Roche Diagnostics, Mannheim, Germany) at a 1:50 dilution. After 15 min, samples were diluted 1:5 and measured by flow cytometric analysis using a FACS-Calibur from Becton Dickinson (Heidelberg, Germany). Cells were analyzed by forward and side scatter and annexin V-fluorescence intensity was measured in the fluorescence channel FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.

Intracellular Ca^{2+} measurements were performed as described [46]. Briefly, erythrocytes from healthy volunteers were loaded with Fluo-3/AM (Calbiochem; Bad Soden, Germany) by addition of 10 μl of a Fluo-3/AM stock solution (2.0 mM in DMSO) to 10 ml erythrocyte suspension (0.16 % hematocrit in Ringer). The cells were incubated at 37°C for 15 min under vigorous shaking and light protection. An additional 10 μl of Fluo-3/AM was added and incubation continued for another 25 min. Fluo-3-AM-loaded erythrocytes were centrifuged at 1000 g for 3 min. at 22°C and washed two times with Ringer solution containing 0.5 % bovine serum albumin

Table 1. Enhanced plasma levels and intraerythrocytic concentrations of methylglyoxal in diabetic patients. Data are means $\pm$ SD.

	n	Subject group	Means $\pm$ SD	Minimum-maximum	P-value
[Methylglyoxal] _{plasma} (nmol/g Hb)	(21)	Control	139 $\pm$ 98	67 - 180	<0.001
	(31)	Diabetic	483 $\pm$ 181	103 - 575	
[Methylglyoxal] _{RBC} (nmol/g Hb)	(21)	Control	1.37 $\pm$ 0.51	0.68 - 2.23	<0.01
	(31)	Diabetic	2.49 $\pm$ 1.94	0.37 - 6.00	

Fig. 1. Effect of methylglyoxal on phosphatidylserine exposure of human erythrocytes. A. Original histograms of annexin-V-binding of erythrocytes incubated for 24 h in the absence (left) or presence (right) of 10 μ M methylglyoxal. B. Means $\pm$ SEM (n = 7) of annexin-V-binding of erythrocytes after 24 h in the absence (control, open bar) or presence (closed bars) of 0.1 μ M, 0.3 μ M, 1.0 μ M, 3.0 μ M and 10 μ M methylglyoxal. *different from control (ANOVA;P<0.05). C. Means $\pm$ SEM (n = 7) of forward scatter of erythrocytes incubated for 24 h in the absence (control, open bar) or presence (closed bars) of 0.1 μ M, 0.3 μ M, 1.0 μ M, 3.0 μ M and 10 μ M methylglyoxal. *different from control (ANOVA;P<0.05).

(Sigma) and one time with albumin-free Ringer. For flow cytometry, Fluo-3/AM-loaded erythrocytes were resuspended in 5 ml Ringer (0.32 % hematocrit) and incubated for different time periods at 37 °C in the presence or absence of methylglyoxal. Then, cells were analyzed by forward and side scatter and Ca²⁺-dependent fluorescence intensity was measured in the fluorescence channel FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. As a positive control to increase intracellular Ca²⁺ activity, erythrocytes were stimulated with 1 μ M ionomycin for 3 min prior to analysis.

Determination of intracellular ATP concentration

Erythrocytes were washed (3 x 5 min) in PBS, centrifuged and 100 μ l of the blood cell pellet were incubated for 48 h at 37°C with standard Ringer solution with or without 30 μ M, 100 μ M or 300 μ M methylglyoxal (final hematocrit ~ 5-7 %). After incubation, cells were lysed in distilled water and proteins were precipitated by HClO₄ (5 %). After centrifugation, an aliquot of the supernatant (400 μ l) was adjusted to pH 7.7 by addition of saturated KHCO₃ solution. All manipulations were performed at 4°C to avoid ATP degradation. After dilution of the supernatant, the ATP concentration of the aliquots was determined utilizing the luciferin-luciferase assay kit (Roche Diagnostics, Mannheim, Germany) and a luminometer (Biolumat LB9500; Berthold, Bad Wildbad, Germany). ATP concentrations are expressed as mmol/l packed erythrocyte volume.

Determination of reduced glutathione (GSH)

Freshly drawn human erythrocytes (6 % hematocrit) were washed twice in PBS and incubated for 24 h or 48 h at 37°C in Ringer solution or glucose-free Ringer solution, in the presence or absence of methylglyoxal (3 μ M). After incubation, cells were again washed twice in PBS. Then, 50 μ l of the erythrocyte pellet was lysed in 200 μ l distilled water and centrifuged at 14,000 g. 150 μ l of the supernatant was deproteinated by adding 150 μ l metaphosphoric acid (10 %). All manipulations after the 24 or 48 h incubation period were performed at 4°C. Glutathione

(GSSG and GSH) was measured with the Glutathione Assay Kit from Cayman Chemicals (purchased from IBL-Hamburg, Hamburg, Germany) according to the manufacturer's protocol. GSH concentrations are expressed in μ mol/l packed erythrocyte volume.

Determination of glucose utilization

Freshly drawn human erythrocytes (6 % hematocrit) were washed twice in PBS and incubated for 48 h at 37°C in Ringer solution (7.2 mM glucose and 0 mM lactate) in the presence or absence of methylglyoxal (300 μ M). Following incubation, glucose (electrochemical measurement by the glucose dehydrogenase method) and lactate (lactate oxidase method and electrochemical determination of H₂O₂) concentrations were determined as described.

Statistics

Data are expressed as arithmetic means $\pm$ SEM and statistical analysis was made by paired or unpaired student's t-test, or by ANOVA using Dunnett's or Tukey's test as post hoc test, where appropriate. $P < 0.05$ was considered statistically significant.

Results

Metabolites known to be increased during hyperglycemia of diabetes include methylglyoxal. To estimate the impact of diabetes on methylglyoxal concentration, a group of 31 type 1 diabetic patients was recruited, and the plasma levels as well as the intraerythrocytic concentrations of methylglyoxal were determined. As shown in Table 1, the methylglyoxal plasma levels of diabetic patients were significantly enhanced by approx. 3.5-fold as compared with the plasma levels of age-matched normal individuals ($n=21$). Interestingly, the diabetic condition not only enhanced the patients' methylglyoxal plasma levels but also led to a significant elevation of intraerythrocytic methylglyoxal by about 82 % (Table 1).

Thus, the effect of methylglyoxal was tested on erythrocytes from healthy individuals. As shown in Fig. 1A,B, methylglyoxal enhanced the phosphatidylserine exposure, an effect statistically significant at concentrations of 0.3 μ M methylglyoxal. As outlined in the methods section, addition of methylglyoxal has been repeated up to 8 times to compensate for methylglyoxal degradation. At concentrations below 10 μ M, methylglyoxal did not significantly affect the forward scatter of the erythrocytes. The exposure to 10 μ M methylglyoxal was, however, followed by a slight, but significant decrease of forward scatter (Fig. 1C).

Both, enhanced phosphatidylserine exposure and decreased forward scatter are typical consequences of increased cytosolic Ca^{2+} activity. Thus, the effect of methylglyoxal on cytosolic Ca^{2+} activity has been tested using Fluo3 fluorescence. As illustrated in Fig. 2, 3 μ M methylglyoxal did not significantly increase cytosolic Ca^{2+} activity up to 6 hours incubation. At concentrations of 10 μ M, methylglyoxal treatment was even followed by a slight but significant decrease of cytosolic Ca^{2+} activity.

Oxidative stress is also known to stimulate phosphatidylserine exposure. To explore whether methylglyoxal influences anti-oxidative defense, reduced (GSH) and oxidized (GSSG) glutathione were determined in erythrocytes from healthy volunteers incubated for 48 hours in Ringer solution without or with 3 μ M

Fig. 2. Cytosolic Ca^{2+} activity in the presence of methylglyoxal. A. Original histograms of Fluo3-fluorescence in erythrocytes incubated for 6 h in the absence (upper left) or presence of 3 μ M (upper right) and 30 μ M (lower left) methylglyoxal or 0.1 μ M ionomycin, as a positive control (lower right). B. Means $\pm$ SEM ($n = 4$) of Fluo3-fluorescence in erythrocytes incubated for 1, 3 and 6 h in the absence (control, open bars) or presence of 0.3 μ M, 3 μ M, 30 μ M methylglyoxal (MG), or for 1 h with 1 μ M ionomycin (black bar). *different from control (ANOVA; $P < 0.05$).

methylglyoxal. As illustrated in Fig. 3, methylglyoxal treatment led to a marked decline of GSH levels without significantly affecting GSSG levels. Glucose depletion, which was used as a positive control for the dissipation of the anti-oxidative defense, similarly decreased the GSH levels.

The decline of GSH levels following methylglyoxal treatment could have resulted from energy depletion. Thus, in the next series of experiments, ATP concentrations were determined in erythrocytes from healthy volunteers incubated for 48 hours in Ringer solution without or with 30 μ M, 100 μ M or 300 μ M

Fig. 3. Effect of methylglyoxal treatment on glutathion levels of human erythrocytes. A. Means $\pm$ SEM ($n = 4$) of annexin-V-binding in erythrocytes prior to ($t = 0$) and following incubation for 48 h in Ringer without or with 300 μ M methylglyoxal (MG), or in glucose-free Ringer (0 Gluc). B. Means $\pm$ SEM ($n = 4$) of reduced glutathione (GSH) and oxidised glutathione (GSSG) in erythrocytes prior to ($t = 0$) and following incubation for 48 h in Ringer without (control) or with 300 μ M methylglyoxal (MG). Additionally, GSH and GSSG concentrations are shown in the absence of glucose (0 Gluc). *different from control (ANOVA; $P < 0.05$).

methylglyoxal. As shown in Fig. 4, the treatment with methylglyoxal indeed led to a significant decrease of erythrocyte ATP concentration, an effect statistically significant at 100 μ M and 300 μ M methylglyoxal. Glucose depletion, which was again used as a positive control, similarly decreased the ATP concentration (Fig.4).

The decline of the ATP concentration could have resulted from impairment of the flux through glycolysis or pentose phosphate pathway. To test for the effect of methylglyoxal treatment on glucose metabolism, the consumption of glucose and formation of lactate were determined in erythrocytes from healthy volunteers incubated for 48 hours in Ringer solution without or with 300 μ M methylglyoxal. As shown in Fig. 5, methylglyoxal treatment indeed significantly decreased lactate production.

Fig. 4. Effect of methylglyoxal treatment on ATP levels of human erythrocytes. A. Means $\pm$ SEM ($n = 4$) of annexin-V-binding in human erythrocytes after 48 h in Ringer without (control) or with 30 μ M, 100 μ M or 300 μ M methylglyoxal, or in glucose-free Ringer (0 Gluc). B. Means $\pm$ SEM ($n = 4$) of ATP concentration in erythrocytes incubated for 48 h in Ringer without (control) or with 30 μ M, 100 μ M or 300 μ M methylglyoxal, or in glucose-free Ringer (0 Gluc). *different from control (ANOVA; $P < 0.05$).

If decreased flux through the glycolytic pathway were sufficient to trigger phosphatidylserine exposure, glucose depletion should be similarly effective as methylglyoxal. As shown in Fig. 6, this was indeed the case. In these experiments, glucose depletion led within 48 hours to marked phosphatidylserine exposure.

Discussion

The present results confirm that diabetes leads to enhanced phosphatidylserine exposure of erythrocytes, a key event in suicidal erythrocyte death or eryptosis. More importantly, the experiments reveal that eryptosis is triggered by methylglyoxal, a metabolite accumulated in sustained hyperglycemia. The stimulation of eryptosis

Fig. 5. Effect of methylglyoxal treatment on glucose utilisation and lactate formation. Means $\pm$ SEM ($n=4$) of extracellular glucose (left) and lactate (right) following erythrocyte incubation for 48 h in Ringer without (control, open bars) or with (hatched bars) 300 μ M methylglyoxal (MG; 6 % Hct). *different from control (ANOVA; $P<0.05$).

by methylglyoxal could contribute to or even account for the triggering of eryptosis in diabetic individuals. The mean plasma concentration of methylglyoxal, which was measured in diabetic patients, amounted to 0.5 μ M, a value which is in the same range as the lowest, effective methylglyoxal concentration (0.3 μ M) significantly inducing phosphatidylserine exposure in our experimental system. However, it should be kept in mind that the *in vitro* measurements were performed in the absence of plasma. Since methylglyoxal reversibly binds to thiol groups of albumin [47], this will decrease the potency of methylglyoxal and thereby inhibit its proeryptotic effect.

Apparently, methylglyoxal is not primarily effective through increase of cytosolic Ca^{2+} activity. An increase of cytosolic Ca^{2+} activity was expected to activate the Ca^{2+} sensitive K^{+} channel (Gardos channel) [48, 49]. The subsequent hyperpolarisation of the cell membrane would drive Cl^{-} out of the cell and the cellular loss of KCl with osmotically obliged water thus lead to cell shrinkage [50, 51]. Loss of cellular K^{+} is considered a requirement of apoptosis in several cell types [52–58] and activation of Ca^{2+} sensitive K^{+} channels participates in the cell shrinkage and deformation of desoxygenized sickle cells [48, 49, 59–61] which have most recently been shown to be highly sensitive to eryptosis following osmotic shock or oxidative stress [62]. However, exposure for 6 hours to 3 μ M methylglyoxal had little effect on forward scatter, suggesting that at those concentrations and exposure times methylglyoxal did not substantially increase cytosolic Ca^{2+} activity. At higher concentrations methylglyoxal even

Fig. 6. Stimulation of phosphatidylserine exposure by glucose depletion. A. Original histograms of Annexin-V-binding of erythrocytes incubated for 48 h in the presence (left) or absence (right) of glucose. B. Means $\pm$ SEM ($n=4$) of annexin-V-binding erythrocytes following 48 h incubation in presence (control, open bar) or absence (black bar) of glucose. *different from control (ANOVA; $P<0.05$).

decreased cytosolic Ca^{2+} activity. On the other hand, millimolar concentrations of methylglyoxal have been shown to increase Ca^{2+} activity in MDCK cells [63].

Methylglyoxal is at least partially effective by an effect on glucose metabolism. Methylglyoxal has previously been shown to interfere with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [64]. The energy depletion compromises the formation of GSH thus interfering with anti-oxidative defense [65]. Besides its effect on cellular GSH levels, methylglyoxal may impede anti-oxidative defense by inactivating glutathione peroxidase [66]. GSH depletion has been observed in

diabetes mellitus and GSH levels have been shown to negatively correlate with diabetic complications, highlighting the pathophysiological significance of weakened anti-oxidative defense [67]. Energy depletion may further impede the function of ATP consuming pumps. Decreased Na^+/K^+ ATPase activity has indeed been observed in erythrocytes from diabetic patients [68].

Methylglyoxal similarly stimulates apoptosis of nucleated cells [69-77], an effect involving oxidative stress and activation of p38 kinase [72, 78, 79]. On the other hand, methylglyoxal could interact with the permeability transition pore of mitochondria [80, 81] and may exert antiapoptotic effects in nucleated cells [82]. Whether or not impaired flux through the glycolytic pathway contributes to the influence of methylglyoxal on apoptosis of nucleated cells has not yet been explored. In the present study, we show that methylglyoxal impedes the anti-oxidative defense of erythrocytes thereby inducing phosphatidylserine exposure. As shown previously, oxidative stress by treating erythrocytes with tert-butylhydroperoxide leads to programmed erythrocyte death [14].

Phosphatidylserine exposing erythrocytes bind to phosphatidylserine receptors at macrophages [6-8], leading to their engulfment and subsequent degradation. Erythrocytic vesicles may further be removed from circulation via scavenger receptors by hepatic Kupffer cells [24, 83-85]. Thus, phosphatidylserine exposure leads to premature clearance of affected erythrocytes from circulating blood. Moreover, enhanced phosphatidylserine exposure may allow adhesion of erythrocytes to the vascular wall [10, 86] leading to impairment of microcirculation [87-89]. On the other hand, phosphatidylserine exposure has been reported to impair adhesion to bovine pulmonary artery endothelial cells [90]. Enhanced adhesiveness of erythrocytes could support hemostasis [20, 91-94] and enhance the risk to develop thrombosis [95]. Along those lines trapping of erythrocytes has been observed in the renal medulla following renal ischemia [96]. Enhanced adherence to endothelial cells has indeed been observed in erythrocytes from diabetic patients [97] and methylglyoxal has indeed been implicated in the pathophysiology of vascular and renal disease [36-42, 98-100]. Thus, methylglyoxal induced phosphatidylserine exposure may contribute to the

development of diabetic microangiopathy. However, methylglyoxal may be effective by further mechanisms, such as crosslinking of matrix proteins [101] or glycosylation of plasma proteins [102].

Premature death of phosphatidylserine exposing erythrocytes may affect the interpretation of glycated hemoglobin (HbA_{1c}) concentration, which is widely used to monitor metabolic control in diabetic patients. The degree of glycation of hemoglobin is a function of blood glucose concentration and the time of exposure, i.e. the life span of the erythrocyte. Our data, together with previous results show that hyperglycemia via methylglyoxal increases the percentage of phosphatidylserine exposing erythrocytes thus decreasing the erythrocyte life span. Accordingly the resulting HbA_{1c} value is lower in patients with reduced erythrocyte life span and does not fully reflect the poor metabolic control. Thus, decreased erythrocyte life span should be considered at the interpretation of HbA_{1c} concentrations, particularly in patients with anemia and high reticulocyte numbers. A recent study demonstrated that the life span of erythrocytes is negatively correlated with glycemia [103]. The average erythrocyte life span averages ~ 80 days in patients with poor metabolic control as compared to the normal range of 123 days [103].

In conclusion, methylglyoxal stimulates phosphatidylserine exposure of erythrocytes at least partially by interfering with glucose utilization, ATP production, GSH formation and anti-oxidative defense. The effect of methylglyoxal contributes to or even accounts for the stimulation of erythrocyte phosphatidylserine exposure in diabetic patients and subsequent anemia and/or diabetic microangiopathy.

Acknowledgements

The authors acknowledge the meticulous preparation of the manuscript by Lejla Subasic and Tanja Loch. This study was supported by the Deutsche Forschungsgemeinschaft (La315/13-1 and international graduate course), the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (Center for Interdisciplinary Clinical Research) 01 KS 9602, and by the IZKF-Graduate School "Molecular Medicine # 1547".

References

- Manodori AB, Kuypers FA: Altered red cell turnover in diabetic mice. *J Lab Clin Med* 2002;140:161-165.
- Caimi G, Serra A, Catania A, D'Asaro S, Montana M, Lo PR, Sarno A: Erythrocyte individual phospholipids and erythrocyte membrane fluidity in subjects with vascular atherosclerotic disease with and without diabetes mellitus of type 2. *Microcirc Endothelium Lymphatics* 1990;6:149-157.
- Jain SK, Palmer M, Chen Y: Effect of vitamin E and N-acetylcysteine on phosphatidylserine externalization and induction of coagulation by high-glucose-treated human erythrocytes. *Metabolism* 1999;48:957-959.
- Kuypers FA, de Jong K: The role of phosphatidylserine in recognition and removal of erythrocytes. *Cell Mol Biol (Noisy -le-grand)* 2004;50:147-158.
- Wilson MJ, Richter-Lowney K, Daleke DL: Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes. *Biochemistry* 1993;32:11302-11310.
- Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM: A receptor for phosphatidylserine-specific clearance of apoptotic cells. *Nature* 2000;405:85-90.
- Henson PM, Bratton DL, Fadok VA: The phosphatidylserine receptor: a crucial molecular switch? *Nat Rev Mol Cell Biol* 2001;2:627-633.
- Messmer UK, Pfeilschifter J: New insights into the mechanism for clearance of apoptotic cells. *Bioessays* 2000;22:878-881.
- Boas FE, Forman L, Beutler E: Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. *Proc Natl Acad Sci U S A* 1998;95:3077-3081.
- Eda S, Sherman IW: Cytoadherence of malaria-infected red blood cells involves exposure of phosphatidylserine. *Cell Physiol Biochem* 2002;12:373-384.
- Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, Schulze-Osthoff K, Wesselborg S: Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. *Cell Death Differ* 2001;8:1197-1206.
- Bratosin D, Estaquier J, Petit F, Arnoult D, Quatannens B, Tissier JP, Slomianny C, Sartiaux C, Alonso C, Huart JJ, Montreuil J, Ameisen JC: Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. *Cell Death Differ* 2001;8:1143-1156.
- Daugas E, Cande C, Kroemer G: Erythrocytes: death of a mummy. *Cell Death Differ* 2001;8:1131-1133.
- Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM: Cation channels trigger apoptotic death of erythrocytes. *Cell Death Differ* 2003;10:249-256.
- Lang KS, Lang PA, Bauer C, Duranton C, Wieder T, Huber SM, Lang F: Mechanisms of Suicidal Erythrocyte Death. *Cell Physiol Biochem* 2005;15:195-202.
- Duranton C, Huber SM, Lang F: Oxidation induces a Cl(-)-dependent cation conductance in human red blood cells. *J Physiol* 2002;539:847-855.
- Huber SM, Gamper N, Lang F: Chloride conductance and volume-regulatory non-selective cation conductance in human red blood cell ghosts. *Pflugers Arch* 2001;441:551-558.
- Dekkers DW, Comfurius P, Bevers EM, Zwaal RF: Comparison between Ca²⁺-induced scrambling of various fluorescently labelled lipid analogues in red blood cells. *Biochem J* 2002;362:741-747.
- Woon LA, Holland JW, Kable EP, Roufogalis BD: Ca²⁺ sensitivity of phospholipid scrambling in human red cell ghosts. *Cell Calcium* 1999;25:313-320.
- Andrews DA, Low PS: Role of red blood cells in thrombosis. *Curr Opin Hematol* 1999;6:76-82.
- de Jong K, Rettig MP, Low PS, Kuypers FA: Protein kinase C activation induces phosphatidylserine exposure on red blood cells. *Biochemistry* 2002;41:12562-12567.
- Arese P, Turrini F, Schwarzer E: Band 3/ complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. *Cell Physiol Biochem* 2005;16:133-146.
- Barvitenko NN, Adragna NC, Weber RE: Erythrocyte signal transduction pathways, their oxygenation dependence and functional significance. *Cell Physiol Biochem* 2005;15:1-18.
- Bosman GJ, Willekens FL, Werre JM: Erythrocyte aging: a more than superficial resemblance to apoptosis? *Cell Physiol Biochem* 2005;16:1-8.
- Rice L, Alfrey CP: The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. *Cell Physiol Biochem* 2005;15:245-250.
- Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szewergold BS: Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes* 1999;48:198-202.
- Faure P, Troncy L, Lecomte M, Wiernsperger N, Lagarde M, Ruggiero D, Halimi S: Albumin antioxidant capacity is modified by methylglyoxal. *Diabetes Metab* 2005;31:169-177.
- Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF: Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. *Metabolism* 2003;52:163-167.
- Lapolla A, Flamini R, Dalla VA, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P: Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. *Clin Chem Lab Med* 2003;41:1166-1173.
- Nemet I, Varga-Defterdarovic L, Turk Z: Preparation and quantification of methylglyoxal in human plasma using reverse-phase high-performance liquid chromatography. *Clin Biochem* 2004;37:875-881.
- Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P: Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. *Mol Nutr Food Res* 2005;49:685-690.
- Uribarri J, Peppas M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycoxidants reduces excessive advanced glycation end products in renal failure patients. *J Am Soc Nephrol* 2003;14:728-731.
- Nagai R, Deemer EK, Brock JW, Thorpe SR, Baynes JW: Effect of glucose concentration on formation of AGEs in erythrocytes in vitro. *Ann N Y Acad Sci* 2005;1043:146-150.
- Thornalley PJ: Modification of the glyoxalase system in human red blood cells by glucose in vitro. *Biochem J* 1988;254:751-755.
- Thornalley PJ, Jahan I, Ng R: Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. *J Biochem (Tokyo)* 2001;129:543-549.
- Berlanger J, Cibrán D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequín JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ: Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. *Clin Sci (Lond)* 2005;109:83-95.

- 37 Bourajjaj M, Stehouwer CD, van Hinsbergh VW, Schalkwijk CG: Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. *Biochem Soc Trans* 2003;31:1400-1402.
- 38 Chang T, Wang R, Wu L: Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. *Free Radic Biol Med* 2005;38:286-293.
- 39 McCarty MF: The low-AGE content of low-fat vegan diets could benefit diabetics - though concurrent taurine supplementation may be needed to minimize endogenous AGE production. *Med Hypotheses* 2005;64:394-398.
- 40 Wang X, Desai K, Clausen JT, Wu L: Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. *Kidney Int* 2004;66:2315-2321.
- 41 Wang X, Desai K, Chang T, Wu L: Vascular methylglyoxal metabolism and the development of hypertension. *J Hypertens* 2005;23:1565-1573.
- 42 Yu PH, Wang M, Fan H, Deng Y, Gubins-Haberle D: Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KK^{AY} mice. *Am J Physiol Endocrinol Metab* 2004;286:E634-E641.
- 43 Di Loreto S, Caracciolo V, Colafarina S, Sebastiani P, Gasbarri A, Amicarelli F: Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1 β and nerve growth factor in cultured hippocampal neuronal cells. *Brain Res* 2004;1006:157-167.
- 44 McLellan AC, Phillips SA, Thornalley PJ: The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. *Anal Biochem* 1992;206:17-23.
- 45 Han LP, Davison LM, Vander Jagt DL: Purification and kinetic study of glyoxalase-I from rat liver, erythrocytes, brain and kidney. *Biochim Biophys Acta* 1976;445:486-499.
- 46 Andrews DA, Yang L, Low PS: Phorbol ester stimulates a protein kinase C-mediated agatoxin-TK-sensitive calcium permeability pathway in human red blood cells. *Blood* 2002;100:3392-3399.
- 47 Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ: Increased Dicarbonyl Metabolism in Endothelial Cells in Hyperglycemia Induces Anoikis and Impairs Angiogenesis by RGD and GFOGER Motif Modification. *Diabetes* 2006;55:1961-1969.
- 48 Bookchin RM, Ortiz OE, Lew VL: Activation of calcium-dependent potassium channels in deoxygenated sickle red cells. *Prog Clin Biol Res* 1987;240:193-200.
- 49 Brugnara C, de Franceschi L, Alper SL: Inhibition of Ca(2+)-dependent K⁺ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. *J Clin Invest* 1993;92:520-526.
- 50 Lang KS, Weigert C, Braedel S, Fillon S, Palmada M, Schleicher E, Rammensee HG, Lang F: Inhibition of interferon-gamma expression by osmotic shrinkage of peripheral blood lymphocytes. *Am J Physiol Cell Physiol* 2003;284:C200-C208.
- 51 Myssina S, Lang PA, Kempe DS, Kaiser S, Huber SM, Wieder T, Lang F: Cl⁻ channel blockers NPPB and niflumic acid blunt Ca(2+)-induced erythrocyte 'apoptosis'. *Cell Physiol Biochem* 2004;14:241-248.
- 52 Bortner CD, Hughes FM, Jr., Cidlowski JA: A primary role for K⁺ and Na⁺ efflux in the activation of apoptosis. *J Biol Chem* 1997;272:32436-32442.
- 53 Bortner CD, Cidlowski JA: Caspase independent/dependent regulation of K(+) , cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis. *J Biol Chem* 1999;274:21953-21962.
- 54 Gomez-Angelats M, Bortner CD, Cidlowski JA: Protein kinase C (PKC) inhibits fas receptor-induced apoptosis through modulation of the loss of K⁺ and cell shrinkage. A role for PKC upstream of caspases. *J Biol Chem* 2000;275:19609-19619.
- 55 Hughes FM, Jr., Bortner CD, Purdy GD, Cidlowski JA: Intracellular K⁺ suppresses the activation of apoptosis in lymphocytes. *J Biol Chem* 1997;272:30567-30576.
- 56 Hughes FM, Jr., Cidlowski JA: Potassium is a critical regulator of apoptotic enzymes in vitro and in vivo. *Adv Enzyme Regul* 1999;39:157-171.
- 57 Montague JW, Bortner CD, Hughes FM, Jr., Cidlowski JA: A necessary role for reduced intracellular potassium during the DNA degradation phase of apoptosis. *Steroids* 1999;64:563-569.
- 58 Perez GI, Maravei DV, Trbovich AM, Cidlowski JA, Tilly JL, Hughes FM, Jr.: Identification of potassium-dependent and -independent components of the apoptotic machinery in mouse ovarian germ cells and granulosa cells. *Biol Reprod* 2000;63:1358-1369.
- 59 Franco RS, Palascak M, Thompson H, Rucknagel DL, Joiner CH: Dehydration of transferrin receptor-positive sickle reticulocytes during continuous or cyclic deoxygenation: role of KCl cotransport and extracellular calcium. *Blood* 1996;88:4359-4365.
- 60 Joiner CH: Cation transport and volume regulation in sickle red blood cells. *Am J Physiol* 1993;264:C251-C270.
- 61 Lew VL, Bookchin RM: Osmotic effects of protein polymerization: analysis of volume changes in sickle cell anemia red cells following deoxy-hemoglobin S polymerization. *J Membr Biol* 1991;122:55-67.
- 62 Lang KS, Roll B, Myssina S, Schittenhelm M, Scheel-Walter HG, Kanz L, Fritz J, Lang F, Huber SM, Wieder T: Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. *Cell Physiol Biochem* 2002;12:365-372.
- 63 Jan CR, Chen CH, Wang SC, Kuo SY: Effect of methylglyoxal on intracellular calcium levels and viability in renal tubular cells. *Cell Signal* 2005;17:847-855.
- 64 Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ: Methylglyoxal can modify GAPDH activity and structure. *Ann N Y Acad Sci* 2005;1043:135-145.
- 65 Beard KM, Shangari N, Wu B, O'Brien PJ: Metabolism, not autoxidation, plays a role in alpha-oxoaldehyde- and reducing sugar-induced erythrocyte GSH depletion: relevance for diabetes mellitus. *Mol Cell Biochem* 2003;252:331-338.
- 66 Park YS, Koh YH, Takahashi M, Miyamoto Y, Suzuki K, Dohmae N, Takio K, Honke K, Taniguchi N: Identification of the binding site of methylglyoxal on glutathione peroxidase: methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185. *Free Radic Res* 2003;37:205-211.
- 67 Thornalley PJ, McLellan AC, Lo TW, Benn J, Sonksen PH: Negative association between erythrocyte reduced glutathione concentration and diabetic complications. *Clin Sci (Lond)* 1996;91:575-582.
- 68 Baldini P, Incerpi S, Lambert-Gardini S, Spinedi A, Luly P: Membrane lipid alterations and Na⁺-pumping activity in erythrocytes from IDDM and NIDDM subjects. *Diabetes* 1989;38:825-831.
- 69 Amore A, Cappelli G, Cirina P, Conti G, Gambaruto C, Silvestro L, Coppo R: Glucose degradation products increase apoptosis of human mesothelial cells. *Nephrol Dial Transplant* 2003;18:677-688.
- 70 Du J, Suzuki H, Nagase F, Akhand AA, Yokoyama T, Miyata T, Kurokawa K, Nakashima I: Methylglyoxal induces apoptosis in Jurkat leukemia T cells by activating c-Jun N-terminal kinase. *J Cell Biochem* 2000;77:333-344.
- 71 Fukuchi J, Hiipakka RA, Kokontis JM, Nishimura K, Igarashi K, Liao S: TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis. *J Biol Chem* 2004;279:29921-29929.

- 72 Fukunaga M, Miyata S, Higo S, Hamada Y, Ueyama S, Kasuga M: Methylglyoxal induces apoptosis through oxidative stress-mediated activation of p38 mitogen-activated protein kinase in rat Schwann cells. *Ann N Y Acad Sci* 2005;1043:151-157.
- 73 Godbout JP, Pesavento J, Hartman ME, Manson SR, Freund GG: Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cdelta. *J Biol Chem* 2002;277:2554-2561.
- 74 Hsuw YD, Chang CK, Chan WH, Yu JS: Curcumin prevents methylglyoxal-induced oxidative stress and apoptosis in mouse embryonic stem cells and blastocysts. *J Cell Physiol* 2005;205:379-386.
- 75 Kim J, Son JW, Lee JA, Oh YS, Shinn SH: Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes. *J Korean Med Sci* 2004;19:95-100.
- 76 Okouchi M, Okayama N, Aw TY: Hyperglycemia potentiates carbonyl stress-induced apoptosis in naive PC-12 cells: relationship to cellular redox and activator protease factor-1 expression. *Curr Neurovasc Res* 2005;2:375-386.
- 77 Takagi Y, Du J, Ma XY, Nakashima I, Nagase F: Phorbol 12-myristate 13-acetate protects Jurkat cells from methylglyoxal-induced apoptosis by preventing c-Jun N-terminal kinase-mediated leakage of cytochrome c in an extracellular signal-regulated kinase-dependent manner. *Mol Pharmacol* 2004;65:778-787.
- 78 Fukunaga M, Miyata S, Liu BF, Miyazaki H, Hirota Y, Higo S, Hamada Y, Ueyama S, Kasuga M: Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. *Biochem Biophys Res Commun* 2004;320:689-695.
- 79 Nagaraj RH, Oya-Ito T, Bhat M, Liu B: Dicarbonyl stress and apoptosis of vascular cells: prevention by alphaB-crystallin. *Ann N Y Acad Sci* 2005;1043:158-165.
- 80 Johans M, Milanese E, Franck M, Johans C, Liobikas J, Panagiotaki M, Greci L, Principato G, Kinnunen PK, Bernardi P, Costantini P, Eriksson O: Modification of permeability transition pore arginine(s) by phenylglyoxal derivatives in isolated mitochondria and mammalian cells. Structure-function relationship of arginine ligands. *J Biol Chem* 2005;280:12130-12136.
- 81 Speer O, Morkunaite-Haimi S, Liobikas J, Franck M, Hensbo L, Linder MD, Kinnunen PK, Wallimann T, Eriksson O: Rapid suppression of mitochondrial permeability transition by methylglyoxal. Role of reversible arginine modification. *J Biol Chem* 2003;278:34757-34763.
- 82 Sakamoto H, Mashima T, Yamamoto K, Tsuruo T: Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. *J Biol Chem* 2002;277:45770-45775.
- 83 Werre JM, Willekens FL, Bosch FH, de Haans LD, van der Vegt SG, van den Bos AG, Bosman GJ: The red cell revisited—matters of life and death. *Cell Mol Biol (Noisy -le-grand)* 2004;50:139-145.
- 84 Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, Bos HJ, Bosman GJ, van den Bos AG, Verkleij AJ, Werre JM: Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. *Blood* 2003;101:747-751.
- 85 Willekens FL, Werre JM, Kruijt JK, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, van den Bos AG, Bosman GJ, van Berkel TJ: Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. *Blood* 2005;105:2141-2145.
- 86 Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. *Br J Haematol* 1999;107:300-302.
- 87 Pawloski JR, Hess DT, Stamler JS: Export by red blood cells of nitric oxide bioactivity. *Nature* 2001;409:622-626.
- 88 Sprague RS, Stephenson AH, Dimmitt RA, Weintraub NL, Branch CA, McMurdo L, Lonigro AJ, Weintraub NA: Effect of L-NAME on pressure-flow relationships in isolated rabbit lungs: role of red blood cells. *Am J Physiol* 1995;269:H1941-H1948.
- 89 Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ: ATP: the red blood cell link to NO and local control of the pulmonary circulation. *Am J Physiol* 1996;271:H2717-H2722.
- 90 Tissot Van Patot MC, MacKenzie S, Tucker A, Voelkel NF: Endotoxin-induced adhesion of red blood cells to pulmonary artery endothelial cells. *Am J Physiol* 1996;270:L28-L36.
- 91 Bergfeld GR, Forrester T: Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. *Cardiovasc Res* 1992;26:40-47.
- 92 Luthje J, Schomburg A, Ogilvie A: Demonstration of a novel ecto-enzyme on human erythrocytes, capable of degrading ADP and of inhibiting ADP-induced platelet aggregation. *Eur J Biochem* 1988;175:285-289.
- 93 Pawloski JR, Swaminathan RV, Stamler JS: Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. *Circulation* 1998;97:263-267.
- 94 Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ: Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. *Circulation* 1998;97:350-355.
- 95 Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. *Blood* 2003;101:4625-4627.
- 96 Lang PA, Warskulat U, Heller-Stilb B, Huang DY, Grenz A, Myssina S, Duszenko M, Lang F, Haussinger D, Vallon V, Wiedner T: Blunted apoptosis of erythrocytes from taurine transporter deficient mice. *Cell Physiol Biochem* 2003;13:337-346.
- 97 Wali RK, Jaffe S, Kumar D, Kalra VK: Alterations in organization of phospholipids in erythrocytes as factor in adherence to endothelial cells in diabetes mellitus. *Diabetes* 1988;37:104-111.
- 98 Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szewergold BS, Mauer M: Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. *Diabetes* 2005;54:3274-3281.
- 99 Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, Strauch C, Du Y, Tang J, Kern TS, Lederer MO, Brownlee M, Weiss MF, Monnier VM: Paradoxical effects of green tea (*Camellia sinensis*) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. *Diabetes* 2005;54:517-526.
- 100 Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyani PA: Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. *Diabetes* 2005;54:2952-2960.
- 101 Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM: Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. *J Biol Chem* 2005;280:12310-12315.
- 102 Ahmed N, Dobler D, Dean M, Thornalley PJ: Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. *J Biol Chem* 2005;280:5724-5732.
- 103 Virtue MA, Furne JK, Nuttall FQ, Levitt MD: Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. *Diabetes Care* 2004;27:931-935.